Clinical advances in proton spatially fractionated radiation therapy

Abstract Spatially fractionated radiation therapy (SFRT) intentionally creates a heterogeneous dose distribution within a tumor, with alternating high-dose peaks and low-dose valleys. This approach offers a different route to dose escalation for bulky, locally advanced tumors and lesions near organs at risk. Proton SFRT (pSFRT) combines this spatial heterogeneity with the finite range of protons, rapid distal dose fall-off, and pencil beam scanning. It may therefore reduce dose outside the target while preserving intratumoral peak-valley patterns. Current pSFRT platforms include proton GRID, proton LATTICE, and proton minibeam radiation therapy, but their clinical maturity differs markedly. Available studies support the technical feasibility and short-term tolerability of pSFRT and suggest potential benefits in tumor control and symptom relief across several cancer types. However, the evidence base is limited by cohort sizes, substantial disease heterogeneity, variability in treatment approaches, frequent use of subsequent radiation therapy or systemic therapy, and relatively short follow-up periods. No included comparative clinical study demonstrated an advantage over photon SFRT or conventional proton therapy. Additional barriers include range and motion uncertainty, inconsistent characterization of peak and valley doses, patient-specific quality assurance, limited radiobiological modeling, and uncertain patient selection. This review examines the evolution of SFRT, the physical rationale for proton delivery, the main pSFRT techniques, published human evidence, and current translational challenges. It also outlines priorities for dose-reporting standards, multicenter prospective studies, and rational integration with systemic therapies, and highlights major unresolved questions that must be addressed before broader clinical application.

Authors

Institutions

Publication Details

Journal
Clinical Cancer Bulletin
Published
2026-11-13
DOI
https://doi.org/10.1007/s44272-026-00079-x
Primary Topic
Radiation Therapy and Dosimetry
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Clinical advances in proton spatially fractionated radiation therapy

Linhan Ye, Shuming Shi, Jiaran Li, Yang Zhang et al.
4 links
Clinical Cancer Bulletin
Radiation Therapy and Dosimetry
article

Clinical advances in proton spatially fractionated radiation therapy

Linhan Ye, Shuming Shi, Jiaran Li, Yang Zhang, Shiwen Hou, Shuanghu Yuan
article en

Abstract

Abstract Spatially fractionated radiation therapy (SFRT) intentionally creates a heterogeneous dose distribution within a tumor, with alternating high-dose peaks and low-dose valleys. This approach offers a different route to dose escalation for bulky, locally advanced tumors and lesions near organs at risk. Proton SFRT (pSFRT) combines this spatial heterogeneity with the finite range of protons, rapid distal dose fall-off, and pencil beam scanning. It may therefore reduce dose outside the target while preserving intratumoral peak-valley patterns. Current pSFRT platforms include proton GRID, proton LATTICE, and proton minibeam radiation therapy, but their clinical maturity differs markedly. Available studies support the technical feasibility and short-term tolerability of pSFRT and suggest potential benefits in tumor control and symptom relief across several cancer types. However, the evidence base is limited by cohort sizes, substantial disease heterogeneity, variability in treatment approaches, frequent use of subsequent radiation therapy or systemic therapy, and relatively short follow-up periods. No included comparative clinical study demonstrated an advantage over photon SFRT or conventional proton therapy. Additional barriers include range and motion uncertainty, inconsistent characterization of peak and valley doses, patient-specific quality assurance, limited radiobiological modeling, and uncertain patient selection. This review examines the evolution of SFRT, the physical rationale for proton delivery, the main pSFRT techniques, published human evidence, and current translational challenges. It also outlines priorities for dose-reporting standards, multicenter prospective studies, and rational integration with systemic therapies, and highlights major unresolved questions that must be addressed before broader clinical application.

Clinical Cancer BulletinVol. 5(1)
University of Science and Technology of China (CN)
National Natural Science Foundation of China, University of Science and Technology of China
Good health and well-being
Radiation Therapy and Dosimetry
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon